The building of a more profitable vaccine industry for the pharmaceutical corporations?
That is the impression taken from this piece.
"Pharmaceutical companies, however, have had little incentive to invest in new technologies" Flu vaccine is relatively cheap and the market is capricious -- millions of doses often end up being discarded because of tepid demand. The long, expensive process of getting new vaccines approved creates another disincentive.
Oh dear, what to do, what to do?
Fortunately for big pharmaceutical companies, a novel pandemic comes along!
Suddenly-the incentive is present, profitability is massive.
There are after all tax extracted dollars to be spent.
And, that long expensive process of getting new vaccines approved?
What long expensive process?
The use of adjuvants- to create more out of less, and I am not talking just vaccine, I am also talking profits.
Adjuvants- compounds that boost the immune response, allowing limited stock to be stretched into more doses.
More doses, more profits!
Luckily, with more taxpayer dollars, new vaccine manufacturing facilities are being built
Spurred by $487 million in federal funding, a sprawling new vaccine factory is opening in North Carolina Tuesday that will produce shots using dog cells instead of chicken eggs.
Over the next few years it is going to get tough, really tough for the big pharmaceuticals companies, so many patents for prescription drugs going generic, nothing new in the works...
Some $135 billion in prescription drug sales will lose patent protection in the next five years, and there's little in drug companies' pipelines to replace those sales. Vaccines are "less vulnerable to generic competition from weaker manufacturers". With the $780 billion global prescription drug market growing at a sluggish 5% a year, many analysts reckon that the vaccine industry, which is forecast to climb 13% annually through 2012, offers the most upside potential.
How to make more money? Vaccines!!! Just look how profitable the swine flu pandemic has been. READ: How Big Pharma Profits from Swine Flu
-GSK says analyst predictions for $1.7 billion of H1N1 vaccine sales in the fourth quarter are broadly accurate, and similar numbers are forecast for the first quarter 2010.
-Novartis says it expects $700 million in fourth-quarter sales alone of its H1N1 pandemic vaccine
- Sanofi-Aventis says it expects H1N1 sales in the fourth quarter to hit $500 million.